N. Janet

发表

Frequency of rare BCR‐ABL1 fusion transcripts in chronic myeloid leukemia patients

B. George, K. Lakshmi, P. Balasubramanian, 2017, International journal of laboratory hematology.

Direct induction of lymphocyte killing by calcium ionophore and phorbol ester treatment.

N. Janet, J. Mikael, A. Maj-Britt, 1987, Cellular immunology.

Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia

B. George, P. Balasubramanian, V. Mathews, 2022, Blood cancer journal.

Arsenic trioxide resistance in acute promyelocytic leukemia: More to it than PML mutations

E. Chendamarai, P. Balasubramanian, V. Mathews, 2020, bioRxiv.

Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide

B. George, P. Balasubramanian, V. Mathews, 2019, British journal of haematology.

NUDT15 c.415C>T Polymorphism Predicts 6-MP Induced Early Myelotoxicity in Patients with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy

B. George, P. Balasubramanian, V. Mathews, 2021, Pharmacogenomics and personalized medicine.

Direct Generation of Immortalized Erythroid Progenitor Cell Lines from Peripheral Blood Mononuclear Cells

P. Balasubramanian, Yukio Nakamura, K. M. Mohankumar, 2021, Cells.

RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.

B. George, K. Lakshmi, P. Balasubramanian, 2015, Pharmacogenomics.

PGPM_A_325813 1303..1313

B. George, P. Balasubramanian, V. Mathews, 2021 .

Myeloproliferative neoplasm with eosinophilia and PDGFR beta rearrangement in an infant

N. Janet, D. Boddu, T. Geevar, 2022, Pediatric blood & cancer.

Systematic application of fluorescence in situ hybridization and immunophenotype profile for the identification of ZNF384 gene rearrangements in B cell acute lymphoblastic leukemia

B. George, P. Balasubramanian, V. Mathews, 2021, International journal of laboratory hematology.

Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients

B. George, K. Lakshmi, P. Balasubramanian, 2020, Scientific Reports.

Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis

Alok Srivastava, Christine Chomienne, Biju George, 2018, Front. Immunol..

Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.

B. George, E. Chendamarai, K. Lakshmi, 2011, Blood.

Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines.

P. Balasubramanian, V. Mathews, E. David, 2023, Leukemia research.

Adult Acute Lymphoblastic Leukemia: Limitations of Intensification of Therapy in a Developing Country

B. George, K. Lakshmi, P. Balasubramanian, 2018, Journal of global oncology.

Prognostic value of MRD monitoring based on BCR-ABL1 copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia

B. George, K. Lakshmi, P. Balasubramanian, 2020, Leukemia & lymphoma.

Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia

E. Chendamarai, P. Balasubramanian, V. Mathews, 2021, Blood advances.

A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide

B. George, P. Balasubramanian, V. Mathews, 2020, Cancer medicine.

Clinical significance of end of induction measurable residual disease monitoring in B-cell acute lymphoblastic leukemia: A single center experience.

B. George, P. Balasubramanian, V. Mathews, 2023, Cytometry. Part B, Clinical cytometry.

Management of relapse in acute promyelocytic leukaemia treated with up‐front arsenic trioxide‐based regimens

B. George, P. Balasubramanian, V. Mathews, 2020, British journal of haematology.